Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cabaletta Bio ( (CABA) ) has provided an announcement.
On May 4, 2026, Cabaletta Bio priced an underwritten registered direct offering of 51,725,000 shares of common stock at $2.90 per share, raising expected gross proceeds of about $150 million and estimated net proceeds of roughly $141 million. The deal, sold at the at-the-market price under Nasdaq rules, is slated to close on or about May 5, 2026, with TD Cowen, Guggenheim Securities, Cantor and H.C. Wainwright & Co. managing the transaction.
The financing attracted participation from Bain Capital Life Sciences, Adage Capital Management, Cormorant Asset Management, Eli Lilly and Company, other existing shareholders and several new mutual and sovereign wealth fund investors. Cabaletta plans to use the proceeds, alongside existing cash, to expand clinical development of rese-cel, advance manufacturing toward commercial readiness and cover working capital, extending its operating runway into mid-2027.
The most recent analyst rating on (CABA) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Cabaletta Bio stock, see the CABA Stock Forecast page.
Spark’s Take on CABA Stock
According to Spark, TipRanks’ AI Analyst, CABA is a Neutral.
The score is held back mainly by weak financial performance (no revenue, widening losses, and heavy cash burn with shrinking equity), partially offset by constructive technical momentum and positive corporate updates that add pipeline and funding runway support. Valuation provides limited support due to a negative P/E and no dividend.
To see Spark’s full report on CABA stock, click here.
More about Cabaletta Bio
Cabaletta Bio, Inc., headquartered in Philadelphia and listed on Nasdaq as CABA, is a late clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies for patients with autoimmune diseases. Its CABA platform underpins engineered T cell therapies, led by rese-cel, a fully human CD19 CAR T cell candidate in the RESET program across rheumatology, neurology and dermatology indications.
The company’s efforts center on advancing CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategies aimed at deep, durable and potentially curative treatments for a broad range of autoimmune diseases. Cabaletta operates its own labs and is expanding clinical and manufacturing capabilities to support eventual commercial readiness for rese-cel and other pipeline assets.
Average Trading Volume: 2,296,370
Technical Sentiment Signal: Buy
Current Market Cap: $327.3M
For detailed information about CABA stock, go to TipRanks’ Stock Analysis page.